70
Participants
Start Date
June 9, 2022
Primary Completion Date
October 31, 2025
Study Completion Date
April 30, 2027
TL-895
TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
Ruxolitinib
Ruxolitinib is an FDA-approved janus kinase inhibitor anticancer drug taken by mouth.
RECRUITING
AP-HM - Hôpital de la Timone, Marseille
RECRUITING
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan
RECRUITING
Hospital Universitari Arnau de Vilanova, Lleida
RECRUITING
Hospital Universitario Ramon y Cajal, Madrid
RECRUITING
Hospital Universitario Virgen de la Victoria, Málaga
RECRUITING
University of Alabama at Birmingham, Birmingham
RECRUITING
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola, Bologna
RECRUITING
Marien Hospital Duesseldorf, Düsseldorf
RECRUITING
Klinik fur Innere Medizin IV - Hamatologie/Onkologie, Universitatsklinikum Hall, Halle
RECRUITING
Gabrail Cancer Center, Canton
RECRUITING
University of Cincinnati (UC), Cincinnati
RECRUITING
CHU Angers, Angers
RECRUITING
Hospital Quironsalud de Zaragoza, Zaragoza
RECRUITING
Centre Hospitalier Lyon Sud, Pierre-Bénite
RECRUITING
Hôpital Saint Louis - AP-HP, Paris
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
CHU de Nice - Hopital L'Archet II, Nice
RECRUITING
Azienda Ospedaliera di Perugia-Ospedale S. Maria della Misericordia, Perugia
RECRUITING
Pratia Onkologia Katowice, Katowice
Telios Pharma, Inc.
INDUSTRY